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1. Introduction
Healthcare-associated infections (HAI) 
have been estimated to affect more than 
4 million patients every year in Europe, 
causing 16 million extra days in hospital 
and leading to approximately €7 billion 
in direct costs.[1] The majority of HAI 
are associated with sometimes invasive 
devices such as ventilators, central lines 
and urinary catheters. Thus, 83% of 
patients with a hospital acquired pneu-
monia were being ventilated, 87% of 
patients with a blood stream infection had 
a device in their blood stream, and 97% 
of patients with a urinary tract infection 
had a urinary tract device in place.[1] The 
risk for acquiring HAI varies between sec-
tors of healthcare and type of patient, with 
patients having burn wounds or trans-
plants as well as neonates and intensive 
care unit (ICU) patients being considered 
high-risk populations.[1] Numbers from 
Antimicrobial Testing
In Europe, the mean incidence of urinary tract infections in intensive care 
units is 1.1 per 1000 patient-days. Of these cases, catheter-associated urinary 
tract infections (CAUTI) account for 98%. In total, CAUTI in hospitals is 
estimated to give additional health-care costs of £1–2.5 billion in the United 
Kingdom alone. This is in sharp contrast to the low cost of urinary catheters 
and emphasizes the need for innovative products that reduce the incidence 
rate of CAUTI. Ureteral stents and other urinary-tract devices suffer similar 
problems. Antimicrobial strategies are being developed, however, the evalua-
tion of their efficacy is very challenging. This review aims to provide consid-
erations and recommendations covering all relevant aspects of antimicrobial 
material testing, including surface characterization, biocompatibility, cytotox-
icity, in vitro and in vivo tests, microbial strain selection, and hydrodynamic 
conditions, all in the perspective of complying to the complex pathology of 
device-associated urinary tract infection. The recommendations should be 
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antimicrobial properties for urinary tract devices in a reliable way.
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2015 solely from ICUs in Europe show that 8% of ICU patients 
develop at least one HAI, 6% acquired pneumonia, 4% blood-
stream infections, and 2% urinary tract infections (UTI). Of 
these, 97% of the pneumonia cases, 43% of blood stream infec-
tions, and 97% of UTIs were associated to invasive devices.[2] 
Moreover, these numbers only relate to patients in hospital 
care, and do not include patients in residential homes, who 
each have one to three infections per year, mainly pneumonia 
and UTI.[1]
A further complication with HAI is the growing resistance 
of pathogenic microorganisms against antimicrobial agents. 
A survey of strains isolated from HAIs in the United States 
between the years 2011 and 2014 showed that resistant strains 
appear more frequently in device-associated infections than 
in surgical-site infections.[3] Resistance to β-lactam antibiotics 
(e.g., oxacillin, methicillin, and cefoxitin) was found in approxi-
mately half of the Staphylococcus aureus strains tested, and mul-
tidrug resistance (i.e., non-susceptible to at least one agent in 
three or more antimicrobial categories[4]) was found in 60–75% 
of Acinetobacter baumannii strains and approximately 20% of 
Pseudomonas aeruginosa strains tested. Carbapenem-resistant 
strains of these species are indicated as priority 1, that is, “crit-
ical,” strains on the recent World Health Organization’s (WHO) 
priority pathogen list, stressing the urgent need for new alterna-
tive treatment methods beside the traditional antibiotics.[5] This 
calls for alternative and complementary methods for combat-
ting device-associated infections. One popular route explored is 
to produce antimicrobial or antifouling materials that prevent 
microbial colonization of the surface. The following antimicro-
bial strategies are typically employed: i) development of anti-/low 
adhesion materials (also referred to as antifouling); ii) systems 
that release antimicrobial agents; iii) contact-killing materials; 
or iv) a combination of these approaches.[6] To assess the efficacy 
of such surfaces, a plethora of methods have been described in 
the scientific literature.[7,8] However, due to a lack of standardi-
zation, the results are very difficult to compare between studies 
and research labs, which delays and limits the progress in this 
field as well as the translation of results to device manufacturing 
and to final clinical use. In other words, in order to increase the 
correlation between in vitro studies of microbial response and 
what can be expected in vivo, it is of great importance that the in 
vitro testing is performed in such a way that the results can have 
clinical significance. Thus, a truly interdisciplinary approach 
is required where material properties, host biocompatibility, 
as well as microbial responses are all evaluated and optimized 
during device development and testing.
This perspective review has been written to provide guidance 
in this context and is a result of work conducted as part of a mul-
tidisciplinary trans-domain European initiative in the framework 
of the COST (European Cooperation in Science and Technology) 
Action TD1305 iPROMEDAI (improved protection of medical 
devices against infection).[9] Through this review, we aim to pro-
vide researchers from the fields of materials science, chemistry, 
physics, and related areas, sufficient background to oversee the 
elements important for clinically relevant microbiological assess-
ment of their antimicrobial materials or devices. Furthermore, 
we aim to provide researchers from the biological and medical 
sciences guidance concerning what types of materials charac-
terization can be employed to obtain increased reproducibility of 
the biological testing and to ensure a solid base for interpreting 
biological assessment of materials and devices. To illustrate how 
experiments can be designed with increased clinical predicta-
bility we use the case of device-associated UTI. However, similar 
reasoning can be employed to design clinically relevant testing 
of medical devices used in other areas of the body, taking into 
account specifics connected to each device group.
2. Device-Associated Urinary Tract Infections
Urological devices are divided into several different market seg-
ments managing, for example, urinary incontinence, urinary 
stones, treatment of prostate hyperplasia or cancer, and erectile 
dysfunction. Devices aimed to manage urinary incontinence or 
maintain the ureter or urethra open and unobstructed, include 
ureteral stents for the upper urinary tract, urethral stents for 
the lower urinary tract, and urinary catheters. The focus of 
this paper is on catheter- and ureteral stent-associated UTI 
(Figure 1) as these are the major device groups and give rise 
to large numbers of infections worldwide.[10] In this review, 
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the term device-associated UTI designates both these types 
of devices. The following clinical needs have been identified: 
a) better methods for diagnosing and quantifying microbial 
colonization, b) development of antimicrobial agents that can 
disrupt and/or prevent formation of biofilms including crys-
talline biofilms, c) development of surface coatings that resist 
and/or reduce microbial adhesion and colonization, as well as 
d) reducing the use of conventional antimicrobial agents in 
order to reduce development of resistance.[11,12]
2.1. Clinical Perspectives
Clinically, the presence of microorganisms (fungi and/or bac-
teria) in urine is diagnosed as UTI only if other symptoms are 
present at the same time (i.e., symptomatic).[13] If no symptoms 
are occurring (asymptomatic) the diagnosis is limited to can-
diduria or bacteriuria if the fungi Candida or bacteria, respec-
tively, are present in the urine. These conditions are not to be 
treated if the patient has no symptoms and does not meet the 
criteria of predisposition for UTI according to clinical guide-
lines.[11,14] The distinction between UTI and bacteriuria or 
candiduria is made in order to reduce the development and 
spread of drug resistance. If more than 105 colony forming 
units of bacteria per mL (CFU mL−1) are cultured from urine 
with no other symptoms, the patient is given the diagnosis of 
asymptomatic bacteriuria.[11] Asymptomatic candiduria in adult 
patients is considered if more than 103 CFU mL−1 of Candida 
are present in the urine without symptoms.[15] Criteria for 
catheter-associated UTI (CAUTI) consist of signs or symptoms 
(such as fever, rigors, and pain) related to UTI and more than 
103 CFU mL−1 of one or several bacterial species detected in a 
urine sample taken from the catheter or up to 48 h after cath-
eter removal[11] in a midstream urine sample.
2.1.1. Pathology of Device-Associated Urinary Tract Infections
Indwelling devices, such as urinary catheters, disturb the local 
host defense mechanisms thereby facilitating the access of bac-
teria to vital organs such as the urinary tract.[16,17] An indwelling 
device may introduce bacteria by transferring the patient’s own 
fecal and/or skin microbiota during insertion, or colonization 
may occur at a later stage through microbial migration along 
the device along extraluminal and/or intraluminal routes.[17,18] 
Microorganisms attached to the surface of the device can form 
a biofilm consisting of cells encapsulated in an extracellular 
matrix of substances that they secrete (Figure 2).[19,20] Biofilms 
are naturally occurring communities of microorganisms, and 
in patients, they protect the microorganisms from the host 
Macromol. Biosci. 2019, 19, 1800384
Figure 1. Anatomical cross section of the renal system in a male showing the position of a urinary catheter in the lower urinary tract (left) and a ure-
teral stent in the upper urinary tract (right). Flow conditions around the devices may vary between the upper and lower urinary tract as well as on the 
intraluminal and extraluminal part of a device. Microorganisms (here exemplified as the fungi C. albicans in purple and the bacterium E. coli in green) 
have been reported to reach the bladder following both extraluminal and intraluminal routes where the extraluminal colonization will have a more 
pronounced contact with the host epithelium in the urethra and may have access to other types of nutrients compared to bacteria residing intralumi-
nally. Furthermore, the device may give rise to an inflammatory response in surrounding tissue that further changes the local growth conditions for 
microorganisms at the device surface. Ureteral stents and urinary catheters are generally colonized both on extraluminal and intraluminal sides and 
often by mixed colonies of microorganisms (not shown in image for simplicity). When bacteria reside on the device for long periods of time (as shown 
on the extraluminal side of the stent above to the right) encrustations may arise due to bacteria-induced precipitation of different types of salts from 
the urine (illustrated by blue and red hexagons).
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immune system as well as from antibiotics. It has been reported 
that bacteria within a biofilm can tolerate more than 1000-fold 
higher antibiotic concentrations than free swimming or sus-
pended (planktonic) bacteria.[21] Bacteria can subsequently be 
released from the biofilm, perhaps stimulated by device move-
ments, and have been estimated to ascend from a catheter to 
the bladder within 1–3 days[11,22] or colonize other parts of the 
device. In both routes of infection (intraluminal and extralu-
minal), bacteria move to the bladder, from where they may (re)
inoculate the intraluminal area of the catheter forming biofilms 
that serve as a persistent and continuous source for recurrent 
bacteriuria. It has been concluded from a prospective clinical 
study, in both men and women, that CAUTIs are predominantly 
caused by microorganisms that gain access extraluminally.[23] 
However, another postinsertion route of infection for catheters 
is when the collecting tube or drainage bag becomes contami-
nated by bacteria, which thereafter migrate and to form biofilm 
intraluminally, and then detach to infect the bladder.[17,18,24] 
After catheter removal, remnants of extraluminal biofilm are 
generally cleared by the immune system and the restored urine 
flow, leading to gradual disappearance of UTI.[11] For ureteral 
stents, the colonization is expected to follow the same or very 
similar routes as for catheters but starting with bacterial con-
tamination of urine in the bladder. Therefore, preventive meas-
ures should ideally not only inhibit bacterial colonization on 
the intraluminal surface of devices, but should prevent coloni-
zation and migration of organisms via all possible routes along 
the device, that is, both intraluminally and extraluminally. In 
addition to this, a very important consideration for materials 
and devices residing in a patient for time periods longer than 
a week, is prevention of encrustation and blockage of ureteral 
stents and urinary catheters. It results from the colonization of 
a particular species of bacteria in the urinary tract (e.g., Proteus 
mirabilis) that give rise to crystalline biofilms.[25,26]
The patient group with device-associated UTI is very het-
erogeneous, and as there is no optimal one-solution-fits-all, 
various device solutions exist. Infections of catheters and 
stents share a number of characteristics. Although literature on 
device-associated UTI mainly addresses CAUTI and its causa-
tive microorganisms (e.g., Escherichia coli, Enterococcus species, 
P. aeruginosa, and Candida species), the same species also cause 
stent-associated UTI.[27] Furthermore, environmental factors, 
such as fluid composition around the different devices, are the 
same or very similar. There can, however, be flow differences 
around the devices depending on their placement in either the 
upper or lower urinary tract, in the bladder, or between the 
intraluminal and extraluminal sides of the devices (Figure 1). 
Furthermore, it can be assumed that the fluid composition may 
be influenced by the surrounding tissue on the extraluminal 
sides, for example, through substances secreted following irri-
tation or damage to the epithelium by the catheter. However, 
if such processes occur within the bladder, similar substances 
will also be present intraluminally. Both the differences in flow 
and fluid composition may influence the microbial composi-
tion, colonization rate, and biofilm formation on the device. 
The microbiota may, therefore, differ in composition and level 
of tolerance to antimicrobial agents depending on the local con-
ditions. Intraluminal flow conditions in the lower urinary tract 
in presence of a catheter will depend on the way the catheter 
is placed (i.e., urethra or suprapubic) and “operated,” that is, 
constant drainage or with a closing tap allowing the bladder 
to fill before voiding. The latter allows for higher flow rates of 
urine through the catheter at voiding. Since the flow through 
the ureters is considered more uniform and constant than 
Macromol. Biosci. 2019, 19, 1800384
Figure 2. Presence of biofilm inside a pigtail stent from a 2-year-old patient visualized by fluorescence in situ hybridization (FISH). A) Overview of a 
longitudinal section of the device (green autofluorescence) shows that its inside is covered by a continuous layer (dark green) with a blue lining toward 
the lumen. B) At higher resolution of the insert, biofilms embedded in a green autofluorescent matrix are visible, partly stained blue with the nucleic 
acid stain DAPI. C) At high resolution of the insert marked in B, FISH detects cocci with the Staphylococcus aureus-specific FISH probe (orange). Note 
the differential signal intensity of the bright orange cocci, indicating a high ribosomal content and therefore activity, versus the blue, resting cells.
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through the urethra, ureteral stents are expected to be exposed 
to a lower flow rate than devices in the lower urinary tract.[28] 
An additional complication of device-associated UTI is that 
uropathogenic E. coli have been shown to invade epithelial cells 
and cause recurrent infections, which may indicate the need 
for devices that can release antimicrobial agents specifically tar-
geting intracellular microorganisms.[29,30]
2.1.2. Device-Associated UTI in Numbers
UTIs are the most frequently occurring type of HAI in Europe 
(27% of HAI) and the United States (36–40% of HAI) followed 
by respiratory tract infections, surgical-site infections, and 
blood stream infections.[1,31] The number of patients with a uri-
nary catheter varies between hospitals as well as between units 
within the same hospital. The reported percentage of patients 
with an indwelling catheter in hospitals and in elderly homes 
varies between studies performed in Europe and United States. 
The percentages also vary between European countries.[32] Liter-
ature suggests that 5–10% of patients in elderly homes are cath-
eterized,[11,24] although percentages as high as 40% have been 
reported.[33] A surveillance report from the European Centre for 
Disease Prevention and Control (ECDC) from 2013 claims an 
average incidence of UTI of 31% in long-term care facilities in 
Europe, the majority of these cases are likely being related to 
CAUTI.[34] In Europe, the mean incidence of UTI in ICUs was 
reported as 1.1 per 1000 patient-days[2] and UTIs occurred in 
1.9% of the patients staying in an ICU for more than 2 days. 
Of these UTI cases, CAUTI accounted for 97.4%.[2] In general 
hospitals, 15–25% of patients have been estimated to have a 
urethral catheter at some time of their stay.[11] In the United 
States, 30 million urinary catheters are inserted every year 
(number based on market reports[35]) and they have an infec-
tion rate of 10–30%.[26,35] Starting on the first day of catheteriza-
tion, a patient has a 3–8% increased risk of acquiring CAUTI 
for each day the urinary catheter remains in place,[11] and these 
infections are reported to increase hospital stay with up to four 
days.[11] One fourth of patients with short term (<7 days) cathe-
terization and all patients who have a catheter in place for more 
than 1 month develop bacteriuria.[36] Not only catheterized 
patients suffer from device-associated UTI, in patients with 
ureteral stents, 38% develop UTI,[37] and 45–100% of patients 
with ureteral stents have bacteriuria.[38]
A cost estimate from 2015 suggests that the annual total 
additional costs for treating CAUTI in the United Kingdom 
is £1–2.5 billion.[16] A rough estimate of total direct hospital 
costs connected to CAUTI in the United States gives a figure 
of $36 billion.[16] An assessment of the economic burden of 
ureteral-stent-related problems published in 2016 illustrates 
that while the ureteral stent is in the price range of one hun-
dred USD, the total cost including drug therapy, healthcare 
professional consultation, hospitalization, and work incapacity 
amounts to a fourfold higher costs per patient (median of $455 
in a span of $113–$11 948).[39] However, the reported range 
shows that in some cases the total cost can increase by a factor 
of 100. The average fourfold increase in costs reported for stents 
in the study by Staubli et al.[39] appears less than the general 
estimates of increased costs for urinary catheters. This indicates 
that more research is needed that can clearly show the full 
increase of health-care costs from device-associated infections 
in these device groups. However, the estimates still illustrate 
that even though device-associated UTIs have been described to 
account for low mortality, they increase morbidity, resource uti-
lization, hospitalization periods, and health care costs. Further-
more, these infections cause increased use of antimicrobials and 
thereby promote the emergence of antimicrobial resistance.[40]
Hospital-acquired CAUTIs are frequently caused by bac-
terial species of Enterobacteriaceae among which extended-
spectrum β-lactamase-producing isolates are prevailing, such 
as Enterobacter aerogenes, Enterobacter cloacae, E. coli, Klebsiella 
pneumoniae, Klebsiella oxytoca, Morganella morganii, P. mira-
bilis, and Serratia marcescens.[31] However, the presence of 
fungi, especially Candida species is of importance and may 
occur simultaneously with a bacterial infection.[15] Indeed, 
infections by Candida species have been reported for 20–30% 
of CAUTI cases.[11,38,41] In Europe, the most frequently iso-
lated organisms are E. coli, Enterococcus species, P. aeruginosa 
and Klebsiella species.[2] The relative ratios between different 
species of pathogens isolated in Europe have been reported 
to remain similar over time (between 2012 and 2014) but 
display geographical variations.[2] Isolates resistant to car-
bapenems (e.g., imipenem and meropenem) were identified 
in high percentages among P. aeruginosa (21–25%), A. bau-
mannii (58–69%), and K. pneumoniae (9–11%).[2,3] Multidrug 
resistance in CAUTI isolates was identified in 5–8% of E. coli, 
9–11% of Enterobacter species, 16–19% of P. aeruginosa, and 
65–76% of A. baumannii strains tested.[3] Up to 10% of ure-
teral stents have been reported to be colonized by Candida spe-
cies resulting in candiduria in about 40% of these cases.[20,27] 
Colonization by these different types of microbes is often 
related to the formation of biofilms, routinely observed on 
urinary catheters and stents, and play a major role in device-
associated UTI.[42] In patients with long-term catheterization, 
the infections are often caused by a combination of different 
microorganisms (i.e., polymicrobial) with P. mirabilis as a 
major pathogen.[11,24,41] This bacterium, from the patient’s 
own fecal flora, colonizes indwelling catheters and produces 
urease, an enzyme that degrades urea thereby increasing uri-
nary pH. This in turn causes stone formation, precipitation 
of salts such as calcium phosphate and struvite, formation of 
crystalline biofilms (described above), and leads to recurrent 
catheter or stent blockages.[25,26]
2.1.3. Devices or Materials Aimed to Reduce UTI
Currently, coatings on urinary-tract devices that release anti-
microbial compounds have only been reported to yield positive 
results for short-term devices (e.g., catheters).[43] Furthermore, 
reviews of the clinical effect of catheters currently on the 
market have pointed out that many clinical studies are too lim-
ited to provide a solid basis for clinical recommendations.[43] 
A review from 2017 of commercially available catheters iden-
tified two main antimicrobial strategies used: silver-coated 
(with a range of different forms of silver) and antibiotic-coated 
(including nitrofural, sparfloxacin, rifampicin, or minocycline) 
catheters.[44] Several solutions are currently at research stage 
Macromol. Biosci. 2019, 19, 1800384
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and have not yet been clinically tested, such as chlorhexidine- 
or triclosan-loaded catheters, or catheters with antimicrobial 
peptides, enzymes, bacteriophages, nitric oxide or zwitterionic 
coatings, other polymer coatings, or liposomes.[44,45] In some 
limited patient groups, the use of antimicrobial catheters has 
been reported to reduce the incidence of CAUTI, for example, 
in diabetic insulin-dependent patients, a high-risk group for this 
type of infections.[46] However, the same study did not observe 
a reduction in CAUTI for patients with acute cerebral infarc-
tion.[46] A parallel multicenter clinical trial (over 7100 patients) 
compared two leading antimicrobial urinary catheters (Bardex 
IC silver alloy catheter and ReleaseNF nitrofural catheter) with 
a standard non-antimicrobial urinary catheter (standard polyte-
trafluoroethylene (PTFE)-coated latex catheter) for efficacy in 
preventing CAUTI, but found no clinically important reduction 
in the rate of symptomatic CAUTI.[47] This was found despite 
results from an earlier study with 180 patients finding a signifi-
cant delay in the onset of bacteriuria for the silver-coated Bardex 
IC catheter with respect to non-coated catheters.[48] In vitro 
assays in a bladder model have shown that none of the cath-
eters on the market prevent encrustation and blockage when 
exposed (1–2 days) to the urease-producing P. mirabilis.[42,49]
Several approaches have been studied for reducing the risk 
of infection of ureteral stents: i) the use of antiadhesive surfaces 
by modifying, for instance, the surface charge, hydrophilicity, or 
roughness; ii) elution of antimicrobials (silver, antibiotics, and 
others), and iii) through a dynamic stent surface (biodegrad-
able ureteral stents).[50] The results of a study with triclosan-
eluting stents showed inhibition of the growth of E. faecalis, 
P. mirabilis, S. aureus, and K. pneumoniae, both in preclinical 
in vitro and in vivo models.[51] However, in clinical trials, the 
results showed limited success.[51–53] Another strategy includes 
antibiotic loading in hydrogel-coated stents.[54] Studies using 
combinations of silver nitrate,[55,56] rifampicin,[57] and cipro-
floxacin[56] have been performed in animal models while stents 
with gentamicin, cefazolin, ceftriaxone, or tobramycin have 
only been tested in vitro.[58] The key challenge in this type of 
device-modification strategies is to preserve and reproduce an 
efficient release of antibiotic during the entire residence time of 
a device in vivo. Furthermore, the release must be large enough 
to efficiently kill the microorganisms in order to prevent bacte-
rial colonization and avoid development of resistance, without 
inducing cytotoxicity. Polymeric coatings have also been inves-
tigated for stents, and negatively charged heparin coatings and 
zwitterionic coatings have shown some promise in reducing 
stent encrustation.[59] Physical mechanisms for removing or 
preventing encrustation are also being tested, for example, 
ultrasound[60] and photodynamic therapy.[61]
2.2. Overview of the Catheter Market in 2018
Urological devices such as catheters are very cheap consumer 
products that sell in large quantities by large multinational 
industries. The scenario for ureteral stents is similar, thus, in 
this section, we will only focus on the urinary catheter market. 
The top three industry challenges that impact the market are: 
i) intense competition, pressuring prices, ii) stringent infec-
tion control regulations affecting the market, and iii) lack of 
patient awareness about various urological devices and their 
success rate.[62] In Europe, currently more than 20 companies 
are active. To remain competitive in this market, participants 
must continue to develop and acquire cost-effective products, 
information technology platforms, and services. The ability to 
maintain a competitive edge depends on a combination of fac-
tors, including regulatory approvals, brand placement, product 
quality, safety, cost effectiveness, and continuous documen-
tation of clinical performance. The urinary catheter market 
is projected to have an annual growth rate of 8.5% and reach 
$2.19 billion by 2022, based on the volume of $1.33 billion 
in 2016.[63] Growth in the market can mostly be attributed to 
factors such as the rising prevalence of urinary incontinence, 
increasing number of surgical procedures across the world, and 
the positive reimbursement scenario for urinary catheters in 
the United States and the Asian countries. The prevalence of 
urinary incontinence is increasing with the increasing obesity 
and rising geriatric population.[63] Vendors offer a wide range 
of devices at competitive prices (Box 1[64]). The dominant ver-
sion of indwelling catheter on the market is the Foley cath-
eter named after its inventor Dr. Frederic Foley, who in 1929, 
designed a catheter with a retaining balloon similar to the one 
still in use today.[16]
Key factors for introduction of new medical devices are 
market acceptance, price level, and regulations. The market for 
clinical care products is especially conservative due to the high-
level evidence demands of many medical practitioners. Fur-
thermore, these products are often sold through tenders, thus, 
introducing the risk that the product cost prevails over health-
care costs related to device-associated infections. Moreover, 
companies may often be reluctant to deviate from standard 
working practice with dramatically different new technologies. 
When it comes to pricing, EU countries currently face financial 
pressure on healthcare budgets. This increased control of costs 
and the desire to improve efficiency, tends to shift focus toward 
the cheapest product according to preset specifications. Finally, 
legal requirements for medical devices need to be implemented 
by manufacturers following regulations on, for example, 
national and European levels.
Thus, it can be expected that in order to be able to bring 
innovative products to the market, high reduction in infection 
rates need to be validated to motivate industry to add such a 
device to their portfolio. Furthermore, any change in price level 
of the products must be justified by prolongation of the infec-
tion-free indwelling time. However, factors such as quality of 
life and overall health care costs will have to be rated higher 
than the pure manufacturing price of devices for any change to 
occur in the market.
3. Materials Characterization for Evaluation of 
Antimicrobial or Antifouling Activity
For accurate and reproducible determination of antimicrobial 
and antifouling effects of materials or devices, it is of great 
importance that the material/device is well characterized so 
that the antimicrobial assays do not give rise to false positive 
and false negative outcomes due to factors like surface hetero-
geneities and presence of contamination. Thus, a basic level of 
Macromol. Biosci. 2019, 19, 1800384
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material characterization is crucial for obtaining reliable data 
on the biological effects of a material.
Factors that can play a large role in bacterial adhesion to 
materials and their antimicrobial performance include the 
chemical composition, physicochemical properties (e.g., sur-
face charge, hydrophobicity/hydrophilicity, topography, and 
roughness), and physicomechanical parameters (e.g., elastic 
modulus and hardness) of the surface.[65–68] As the biological 
testing is influenced mainly by surface properties, surface sen-
sitive methods should be chosen that can show if there are sur-
face contaminations, heterogeneities, or alterations of surface 
characteristics caused for example by the presence of antimicro-
bial agent(s), leachable components of the bulk material, or by 
preconditioning of the tested materials. Methods that are com-
monly used in this context are summarized in Figure 3 and will 
shortly be described in this section with supporting references 
for further reading. Many materials are preconditioned by dis-
solved constituents (e.g., proteins) in biological fluids and this 
may affect the outcome of the testing. Thus, characterization of 
a material or device should be performed both before and after 
exposure to relevant culture medium or biological solutions 
(e.g., urine). Furthermore, control samples relating to untreated 
or uncoated materials should be included in all material testing 
steps. As materials and devices will have to be sterilized prior 
to use, it is also highly advisable that suitable sterilization 
methods are investigated early on in the research and develop-
ment process, as well as their effect(s) on the produced mate-
rial/device. Standardized procedures exist for several methods 
concerning materials characterization (some examples listed in 
Table 1).
3.1. Materials Used in Urinary Tract Devices
The majority of materials used in urinary tract devices are poly-
mers and the predominant material is high temperature vul-
canized polydimethyl siloxane (PDMS), also known as silicone 
rubber. Materials such as natural rubber and polyurethane (PU) 
are also used[44,69] as well as metals or metal alloys for ureteral 
stents.[70] The chemical nature of the bulk material, composi-
tion and processing technologies differ between these mate-
rials. Generally, additives are incorporated to different extent 
in order to improve processing and product properties. These 
additives include crosslinker/vulcanizing agents, catalysts for 
the vulcanization, reinforcing fillers, oils, and antiaging agents. 
Thus, on the surface of a polymeric material, low molecular 
weight ingredients and additives may be present, as well as 
degradation products formed during the processing of the 
polymer.[71] On the surface of metal ureteral stents, substances 
protecting against corrosion may be present. For antimicrobial 
materials, leachable antimicrobial agents can also be present at 
the surface[72] and be released from the material during testing 
or usage.
The quantity of leachable substances (including antimicro-
bial agents) can be estimated after extraction with a suitable 
solvent and analysis by chromatography, spectroscopy, and 
other techniques as described in, for example, the ISO 10993-
18:2005 standard (Table 1).[73] Other standards related to chem-
ical characterization of materials are the ASTM F2038-00(2011) 
standard[74] dealing with the chemical requirements of raw and 
medical-grade silicone materials, and the ASTM F2042-00(2011) 
standard[75] that describes the requirements for fabrication and 
testing of medical-grade silicone materials. A general difference 
between medical-grade silicone and industrial-grade silicone 
is a lower level of extractable substances in the low-molecular 
weight range in the former.[76] These extractables include 
impurities from the raw material, residual mono mer catalyst, 
and leachable additives. The amount of residual monomer 
and catalyst can be reduced during postcuring completing the 
crosslinking of the polymer, and thereby reducing amounts 
of residues that may induce toxicity.[69] As medical-grade sili-
cone contains lower amounts of extractables, and therefore is 
expected to give rise to more reproducible data this grade of 
silicone may be better suitable as a general reference material 
during testing than industrial-grade silicone.
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Box 1 Leading vendors of urinary catheters in 2018.
• Bard Medical has the largest portfolio of urinary cath-
eter products globally, including Foley urinary catheters, 
collection systems, irrigation trays, and intermittent uri-
nary catheters. They got the first patents rights for Foley 
catheters in the 1930s. For Foley urinary catheters, they 
offer silver alloy coating technology (licensed from Bac-
tiguard, including an alloy with silver, palladium, and 
gold), latex hydrogel coating, latex-free silicone urinary 
catheter with hydrogel coating, and a silicone-elastomer 
coated latex moisture-repellent Foley urinary catheter. 
Bard acquired the company Rochester Medical in 2013 
adding the Rochesters nitrofurazone coated antimicro-
bial Foley catheter to their portfolio.
• B. Braun offers the Urimed Cath indwelling Foley uri-
nary catheter for both regular and postoperative bladder 
drainage and irrigation. This is made of pure uncoated 
silicone with a relatively large lumen that reduces the 
tendency to encrust and block.
• Boston Scientific have developed a balloon urinary 
catheter technology, the UroMax Ultra High Pressure 
Balloon urinary catheter. It is designed with specially 
treated polymers and processes to provide maximum 
strength to maintain its outer diameter during inflation, 
and ureteral catheters designed with a variety of tip con-
figurations and sizes to facilitate access.
• Coloplast produces the Soft Latex Foley urinary catheter 
and a silicone Foley urinary catheter. They also produce 
Folysil, a long-term all-silicone indwelling catheter with 
up to 12 weeks indwelling time.
• Medtronic offers hydrogel-coated latex Foley urinary 
catheters, silicone-coated latex Foley urinary catheters, 
and silicone elastomer-coated latex Foley urinary cath-
eters. Medtronic recently acquired Covidien adding the 
antimicrobial Dover silver-coated catheter to their port-
folio. They also offer catheters with temperature sensing 
aimed at ICUs.
• Teleflex sells Foley catheters under the brand name 
Rüsch.
www.advancedsciencenews.com www.mbs-journal.de
© 2019 The Authors. Published by WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim1800384 (8 of 26)
3.2. Preconditioning and Characterization of Preconditioned 
Surfaces
When materials are in contact with biological (body) fluids, 
a layer of adsorbed biological substances generally forms at 
their surfaces. These substances may completely change sur-
face properties such as chemistry, roughness and topography, 
(Figure 4).[70,77,78] This layer is called a preconditioning layer 
as it preconditions the surface for cells and microorganisms 
affecting their ability to anchor and colonize.[77,79] Thus, the 
biological response obtained from testing will often be of the 
preconditioned surface rather than the bare/raw material.[80] 
To account for such processes, a comparative characteriza-
tion of the material surface before and after preconditioning 
is required. This is one important reason why material testing 
should be performed in standardized solutions that have clin-
ical relevance, as the preconditioning from synthetic growth 
media may be very different from the same process in body 
fluids, and may vary between different body fluids. Further-
more, preconditioning from different body fluids may influ-
ence microbial species and strains in different ways. As an 
example, fibrinogen deposition following pretreatment with 
blood plasma has been shown to increase the attachment of 
some bacterial species (e.g., S. aureus and some Staphylococcus 
epidermidis strains) but not others (Gram-negatives and other 
S. epidermidis strains).[81,82]
3.3. Surface Chemical Characterization
The interactions between the material and mammalian cells, 
fungal cells and bacterial cells investigated during biological 
testing will, to a large extent, be influenced by the surface 
chemistry and how this chemistry is altered during surface 
preconditioning.[67,78,83] Thus, data showing the overall chem-
ical composition of the surface may enable more detailed 
understanding of the mechanisms governing the colonization 
processes, as well as serve as a quality control for the material 
processing. Analytical methods generally used for this purpose 
include attenuated-total-reflectance Fourier-transform infrared 
spectroscopy (ATR-FTIR, giving information regarding the top 
few µm of a surface), grazing-angle FTIR, and X-ray photo-
electron spectroscopy (XPS, information depth of a few nm).
XPS is used for elemental and functional group analysis of 
top atomic layers of a surface, qualitative and semiquantita-
tive, thus enabling detection of surface contamination, leached 
substances, preconditioning layers, as well as changes in the 
surface chemical composition as a result of oxidation, chem-
ical interaction with antimicrobial agents, etc. Conventional 
XPS instruments operate at ultra-high vacuum. Consequently, 
samples will be exposed to vacuum during analysis, which 
may result in disappearance of volatile substances from the 
surface. To reduce such evaporation the samples may be ana-
lyzed at low temperatures (e.g., frozen using liquid nitrogen) 
or using ambient pressure XPS, which enables the analysis of, 
for example, highly hydrated materials such as hydrogels. For 
more information about XPS, the reader is suggested to consult 
previously published reviews.[84]
ATR-FTIR or grazing angle FTIR (the latter for reflective sur-
faces) can be used to characterize the surface composition with 
respect to chemical functional groups. However, it is important 
to note that FTIR measurements will in general exhibit a larger 
analysis depth than XPS and generally include signal from bulk 
layers below the surface or below a surface coating (depending 
on coating thickness). Thus, it may not be possible to distin-
guish differences in surface chemical composition from bulk 
material unless the coating gives rise to unique vibrations at 
high enough intensity to be detected unambiguously. The use 
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Figure 3. Scheme outlining commonly used methods for materials characterization before biological testing. The following abbreviations are used in 
the figure and text: XPS, X-ray photoelectron spectroscopy; FTIR, Fourier-transform infrared spectroscopy; EDS, energy dispersive spectroscopy (often 
used in combination with EM); ELS, electrophoretic light scattering; SP, streaming potential; SPM, scanning probe microscopy; AFM, atomic force 
microscopy; EM, electron microscopy; TEM, transmission electron microscopy; SEM, scanning electron microscopy. Top surface relates to outermost 
nm (10 nm or less). Surface relates to outermost µm of a surface.
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of FTIR to study materials has previously been well described 
by several authors.[85]
Complementary methods that can be used in addition to 
XPS and FTIR are, for example, ellipsometry, to determine the 
layer thickness of a coating on a reflective surface; dynamic 
secondary-ion mass spectrometry (DSIMS), to determine the 
elemental composition of the surface of materials in the ppm–
ppb range; time-of-flight secondary-ion mass spectrometry 
(ToF-SIMS), to obtain both elemental and molecular surface 
information with low detection limits; nuclear magnetic reso-
nance (NMR) spectroscopy, for chemical information; as well 
as X-ray diffraction (XRD), for identification and information 
about crystallinity for crystalline or partly crystalline materials.
3.4. Surface Topography and Roughness
Surface roughness and topography are parameters that can 
significantly influence attachment of microorganisms and 
subsequent biofilm formation. For example, if the roughness 
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Table 1. Summary of standards mentioned in the review (please note that they are regularly revised and updated).
Standard Title
ASTM F2038-00(2011) Standard guide for silicone elastomers, gels, and foams used in medical applications—Part I: Formulations and uncured materials
ASTM F2042-00(2011) Standard guide for silicone elastomers, gels, and foams used in medical applications—Part II: Crosslinking and fabrication
ISO/DTS 19278 Plastics: Instrumented micro-indentation test for hardness measurement of plastics materials
ASTM D395-16e1 Standard test methods for rubber property: Compression set
ISO 37:2017 Rubber, vulcanized or thermoplastic: Determination of tensile stress–strain properties
ISO 7619-1:2010 Rubber, vulcanized or thermoplastic: Determination of indentation hardness—Part 1: Durometer method (Shore hardness)
ISO 527-1:2012 Plastics: Determination of tensile properties—Part 1: General principles
ISO 527-2:2012 Plastics: Determination of tensile properties—Part 2: Test conditions for molding and extrusion plastics
ISO 868:2003 Plastics and ebonite: Determination of indentation hardness by means of a durometer (Shore hardness)
ISO 604:2002 Plastics: Determination of compressive properties
ISO 14630 Non-active surgical implants: General requirements
ISO 20696 Sterile urethral catheters for single use
EN 1616 Sterile urethral catheters for single use
ASTM F623-99(2013) Standard performance specification for Foley catheter
ASTM F1828-17 Standard specification for ureteral stents
FDA Analytical procedures and methods validation for drugs and biologics: Guidance for industry
ISO 10993-1:2018 Biological evaluation of medical devices—Part 1: Evaluation and testing within a risk management process
ISO 10993-2:2006 Biological evaluation of medical devices—Part 2: Animal welfare requirements
ISO 10993-3:2014 Biological evaluation of medical devices—Part 3: Tests for genotoxicity, carcinogenicity and reproductive toxicity
ISO 10993-4:2017 Biological evaluation of medical devices—Part 4: Selection of tests for interactions with blood
ISO 10993-5:2009 Biological evaluation of medical devices—Part 5: Tests for in vitro cytotoxicity
ISO 10993-6:2016 Biological evaluation of medical devices—Part 6: Tests for local effects after implantation
ISO 10993-7:2008 Biological evaluation of medical devices—Part 7: Ethylene oxide sterilization residuals
ISO 10993-8:2000 Biological evaluation of medical devices—Part 8: Selection and qualification of reference materials for biological tests
ISO 10993-9:2009 Biological evaluation of medical devices—Part 9: Framework for identification and quantification of potential degradation products
ISO 10993-10:2010 Biological evaluation of medical devices—Part 10: Tests for irritation and skin sensitization
ISO 10993-11:2017 Biological evaluation of medical devices—Part 11: Tests for systemic toxicity
ISO 10993-12:2012 Biological evaluation of medical devices—Part 12: Sample preparation and reference materials
ISO 10993-13:2010 Biological evaluation of medical devices—Part 13: Identification and quantification of degradation products from polymeric medical devices
ISO 10993-14:2001 Biological evaluation of medical devices—Part 14: Identification and quantification of degradation products from ceramics
ISO 10993-15:2000 Biological evaluation of medical devices—Part 15: Identification and quantification of degradation products from metals and alloys
ISO 10993-16:2017 Biological evaluation of medical devices—Part 16: Toxicokinetic study design for degradation products and leachables
ISO 10993-17:2002 Biological evaluation of medical devices—Part 17: Establishment of allowable limits for leachable substances
ISO 10993-18:2005 Biological evaluation of medical devices—Part 18: Chemical characterization of materials
ISO/TS 10993-19:2006 Biological evaluation of medical devices—Part 19: Physico-chemical, morphological and topographical characterization of materials
ISO/TS 10993-20:2006 Biological evaluation of medical devices—Part 20: Principles and methods for immunotoxicology testing of medical devices
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and topography are in the same length scale as a bacterium, 
this may enable it to adhere, protected “inside” the topog-
raphy (Figure 5) with increased numbers of sites of interac-
tion with the material.[86,87] Thus, analysis techniques that 
can give information about surface morphology are valuable 
tools for interpreting and understanding microbial interac-
tions with a surface. Furthermore, microorganisms may alter 
the roughness and topography at contact with the surface by 
secreting extracellular polymeric substances (EPS) that may 
penetrate and smoothen surface topographies.[88] Precon-
ditioning from culture medium may induce similar altera-
tions of surface morphology. Scanning probe microscopy 
(SPM), transmission electron microscopy (TEM), and scan-
ning electron microscopy (SEM) are techniques that ben-
eficially can be used to observe the surface morphology and 
topography.[89]
Scanning probe microscopy such as scanning force micro-
scopy (SFM)/atomic force microscopy (AFM) can be used to 
observe and measure surface roughness. These techniques can 
also show presence of pinholes in surface coatings, scratches, 
or other irregularities. AFM has the advantage that it can 
be used to analyze surfaces in fluid. SEM is a complemen-
tary method that can be used in addition to AFM enabling a 
larger span of magnifications to be used than what is routinely 
obtained using AFM. If the electron microscope holds energy 
dispersive spectroscopy (EDS) analysis capabilities, this can be 
used in parallel to investigate the presence and distribution of 
specific elements such as silver, zinc, and titanium within the 
material. For some materials, it may also be advantageous to 
perform thin sectioning and analyze the material using TEM. 
Such sectioning may give information about surface rough-
ness, coating thickness, and distribution of, for example, metal 
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Figure 4. Illustration of a process forming a surface conditioning film exemplified on the surface of a ureteral stent. These preconditioning films can 
also include proteins, lipids, and other biomolecules. Reproduced with permission.[70] Copyright 2017, Elsevier.
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particles within the depth of a coating/material. Both SEM and 
TEM are vacuum techniques although instrumentation exists 
that can analyze samples at more ambient conditions or at cryo-
genic temperatures.[90]
3.5. Surface Charge
Surface charge of a material may produce repulsive or attrac-
tive forces between microorganisms and a material. In general, 
microorganisms exhibit negative surface charges resulting, 
for example, from functional groups such as carboxylates and 
phosphoryl groups.[91,92] Thus, microorganisms are often to 
some extent repelled by negatively charged surfaces, although 
exceptions exist. Charge interaction between a microorganism 
and a surface may increase or decrease adhesion depending on 
both the amount of charges, their nature, as well as the ionic 
strength of the surrounding liquid between the microorgan-
isms and the material.[93] At higher ionic strength, electro-
static forces are reduced due to increased screening of surface 
charges from ions in the electric double layer forming around a 
charged particle and/or on top of the substrate material.[93] The 
charge of particulate materials or of microbial cell surfaces can 
be studied in particular by microelectrophoresis techniques[93] 
such as electrophoretic light scattering (ELS) in which charged 
particles move in an applied electric field while their movement 
is monitored through dynamic light scattering techniques.[91] 
The charge of macroscopic surfaces (in particular capillaries) is 
assessed by means of streaming current or streaming potential 
measurements. For further reading, please consult previously 
published reviews on this topic.[91,93,94]
3.6. Hydrophilic–Hydrophobic Surface Properties and 
Surface Energy
The hydrophilic/hydrophobic property of a surface has been 
identified as an important factor controlling microbial adhesion 
in a number of publications.[65,95] Furthermore, the major route 
of catheter colonization, that is, transmission of bacteria from 
the urinary tract to the extraluminal surface of the catheter, has 
been suggested to be governed by a thermodynamic transfer 
balance that determines whether it is thermodynamically 
favorable for bacteria to transfer from the tissue to the catheter 
surface or not. This balance is based on surface tension of bac-
teria, tissue and the catheter surface.[96]
To analyze the hydrophobicity or hydrophilicity of a surface, 
several methods exist but the most commonly used is contact 
angle goniometry. A small drop of liquid is carefully placed at 
the surface of the material and the angle between the liquid 
drop and the material is measured. This angle will be influ-
enced by the free energy of the surface as well as the surface 
roughness, relative humidity and temperature. For this reason, 
it is of great importance that contact angle data are interpreted 
together with information on these parameters. Equilibrium 
contact angle measurement, that is, analysis of the contact 
angles of a static drop at the surface, are often performed using 
at least three liquids with known surface tension such as water, 
ethylene glycol, and hexadecane. For a more detailed inter-
pretation of the surface free energy, dynamic contact angles 
such as advancing and receding angles are measured.[97] Sur-
face free energy can be calculated from these contact angles 
together with information about the surface tension of the 
liquids according to, for example, Fowkes’ equation or more 
accurately from the Lifshitz van der Waals/acid base approach 
that includes both polar and non-polar components.[98] The sur-
face tensions can also be calculated based on Hansen solubility 
parameters.[99] Further information about contact angle meas-
urements and determination of surface free energy of materials 
can for example be found in review articles by Marmur,[97] and 
for bacterial cells by van der Mei et al.[100]
3.7. Elasticity and Hardness
The effect of physicomechanical properties such as mate-
rial hardness on microbial adhesion has recently emerged as 
a topic of increased interest.[68,101] Depth-sensing indentation 
provides detailed information about physicomechanical char-
acteristics, such as indentation elastic modulus, indentation 
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Figure 5. Illustration of how both surface roughness and topography can influence interactions between microorganisms and a surface. The blue curve 
illustrates the roughness of a surface in the x–z plane (with length scales shown on the two coordinate axes in µm) while the yellow spheres represent 
spherical microorganisms. Ra represents average roughness and Rz represents average difference between highest and lowest points. (a) and (b) have 
identical average roughness but the topographical differences would enable the illustrated organisms to more easily interact with surface (a) compared 
to surface (b). Reproduced with permission.[86] Copyright 2011, Elsevier.
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hardness, dynamic hardness, of a material with probing depth 
of µm to nm.[102] A dynamic ultramicrohardness meter can be 
used to test surface mechanical parameters under different test 
conditions, such as loading force and speed, as well as depth of 
penetration.[103] Regarding this technique, an ISO standard is 
under development.[104]
Additional physicomechanical testing that may be of interest 
for antimicrobial materials are measures of tensile strength, 
compression resistance, and hardness.[105] These parameters 
may be important to monitor in cases where the antimicro-
bial agents are included in the bulk of the material and can 
influence its mechanical properties. Standard ISO tests exist 
for such testing and should include identical material/device 
without antimicrobial agents as a control and are device spe-
cific; EN 1616, DS/EN ISO 20696, and ASTM F623-99(2013) 
are used for urinary catheters and ASTM F1828-97, ASTM 
F1828-17, and ISO 14630 for ureteral stents.[106]
3.8. Pharmaceutical Characterization
Pharmaceutical characterization of drug-releasing antimicro-
bial agents is made by studying in vitro release kinetics.[107] 
This pharmaceutical characterization is compound-dependent 
and the methods selected should allow for assessment of the 
amount of active compound released over time. Thus, the anti-
microbial mode of action of the test material, such as release, 
surface killing and non-adhesiveness, should be known before-
hand, as well as pharmaceutical information of the active 
molecules regarding the mechanism of action, antimicrobial 
spectrum, and effective concentrations (dose response). The 
background information should also include information about 
local or systemic effects, toxic concentrations, and half-life of 
the biological effect.
To study the in vitro release kinetics of an active compound 
from a urinary medical device, release assays are predominantly 
carried out under sink conditions, that is, with sufficient solu-
tion to allow for complete dissolution or release, usually under 
shaking. Nevertheless, testing catheter specimens connected 
to flow systems is also an important approach.[108] Under sink 
conditions, the test device or device segment is immersed in 
a fluid with daily replacement of the fluid. If the device or its 
coating is intended to dissolve slowly then dissolution should 
also be assessed in the fluid. Another important aspect is that 
the in vitro drug release/elution kinetics should be evaluated 
under appropriate conditions, such as media, pH, agitation, 
flow and temperature, based on the mechanism of drug release 
and it should mimic hydrodynamic aspects of the location of 
catheter/stent used. The amount of drug released should be 
assessed periodically by removal and analysis of aliquots. Usu-
ally, the drug can be quantified using high-performance liquid 
chromatography (HPLC) using Pharmacopeia methods. A suit-
able method validation should also be included, for example, 
using Food and Drug Administration (FDA) guidelines from 
the United States.[109] As elution studies should be designed to 
reach a plateau or reach at least 80% of release of the expected 
drug content, the total content of the drug needs to be known 
beforehand. The elution data should be reported as cumulative 
percentage of total drug content eluted over time from at least 
six samples per testing variable.[110] Different mathematical 
models exist to predict release kinetics following different paths 
such as dissolution, diffusion, portioning, osmosis, swelling 
and erosion.[111] Examples of how different models have been 
used to describe release kinetics can, for example, be found in 
Malcolm et al. that described the release kinetics of metronida-
zole from self-lubricating silicone using t1/2 kinetics (Higuchi 
kinetics).[112] This was also used by Fong et al. to describe chlo-
rhexidine released from polyurethane nano composites,[113] 
while Irwin et al. described release of nalidixic acid from 
nalidixic acid-loaded polymers (poly methyl methacrylate-co-
2-hydroxyethylmethacrylate, p(MMA-co-HEMA)) by the Kors-
meyer-Peppas model equation.[114]
4. Biocompatibility and Cytotoxicity Testing
Biocompatibility, is in general, assessed through biological 
evaluation tests included in existing well-established standards 
for medical devices such as ISO 10993. When performing these 
tests, all the aspects in the standard that are raised regarding 
antifouling or antimicrobial materials should be considered. 
Cytotoxicity, sensitization, and irritation or intracutaneous 
reactivity tests are recommended to evaluate biological effects 
of devices in contact with skin or mucosa. In addition, if the 
device is in contact with mucosa and needs to be used for more 
than 30 days, genotoxicity evaluation is necessary.
The ISO 10993 standard consists of 20 parts (Table 1). The 
most relevant parts for cytotoxicity testing of medical devices 
such as urinary catheter and ureteral stents are Part 1: evalu-
ation and testing within a risk management process,[115] Part 
3: tests for genotoxicity, carcinogenicity, and reproductive tox-
icity,[116] Part 5: tests for in vitro cytotoxicity,[117] Part 10: tests 
for irritation and skin sensitization,[118] and Part 12: sample 
preparation and reference materials.[119] Here we will only give 
a brief overview of information included in some of these parts.
Part 3 is used to evaluate the potential genotoxicity, carcino-
genicity, or reproductive and development toxicity of a medical 
device. These tests must be performed if the biomaterial or 
medical device in some way may interact with genetic material, 
or if the composition of the biomaterial is not known. Testing 
for genotoxicity is required for medical devices with long-term 
(>30 days) contact time. A series of in vitro tests can be selected 
(at least two tests with different end-points) and mammalian 
cells must be used. If any of the in vitro toxicity tests yields a 
positive result, in vivo mutagenicity tests are required as well.[116]
In Part 5, in vitro cytotoxicity test methods for medical 
devices in contact with or close vicinity to mammalian cells 
are described with information on experimental conditions. 
For evaluation of cytotoxicity, three different approaches can be 
followed: i) extract test; ii) direct contact test, and iii) indirect 
contact test. The choice of one or more approaches depends on 
the nature of the sample and the nature of the use and implan-
tation site. For example, if an active compound does not leach 
from the sample, the extraction test can be excluded. Cytotox-
icity can be assessed with different endpoints such as by evalu-
ating cell morphology, cell damage, cell growth, or measuring 
cell metabolic activity. Experimental protocols for these assays 
are provided in this ISO standard. The test sample can be the 
Macromol. Biosci. 2019, 19, 1800384
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material or the extract (obtained under sterile conditions). Posi-
tive and negative controls should be selected based on materials 
that are known to induce cytotoxic and non-cytotoxic responses, 
respectively. For the extracts, the blank control (i.e., extraction 
medium) must also be tested.[117] When evaluating cytotoxicity 
of materials aimed to be used in the urinary tract, suitable cell 
lines from the urinary tract should be used including epithelial 
cell lines.
The way to assess if the medical device/material causes irrita-
tion or skin sensitization is described in Part 10. The following 
aspects are considered: pretest considerations for irritation 
(including in silico and in vitro methods for dermal exposure), 
details of in vivo (irritation and sensitization) test procedures, 
and key factors for the interpretation of the results. The in vitro 
skin model irritation assay is based on the premise that irri-
tant chemicals can penetrate the stratum corneum by diffusion 
and are cytotoxic to the underlying cells, as detected by micros-
copy/histology. If the cytotoxic effect is only weak or absent and 
cannot be detected, released inflammatory mediators may be 
evaluated in addition.[118]
Sample preparation and choice of suitable references are 
described in Part 12, which addresses the following topics: test 
sample selection; selection of representative portions from a 
device; test sample preparation; experimental controls; selec-
tion of, and requirements for reference materials; and prepa-
ration of extracts. It also highlights that biological evaluation 
must be performed on the final product (e.g., representative 
samples, materials processed similarly or adequate extracts). 
A solvent extraction can be used to extract the chemicals that 
could possibly leach from the biomaterial and the extract 
should be obtained under conditions that mimic the physi-
ological reality and are appropriate for the sample being tested. 
The solvents to be used and extraction conditions (e.g., time, 
temperature) are also described in Part 12.[119] For comparison 
between bacterial exposure and cell exposure, culture medium 
with similar chemical composition should be used. For 
example, if compounds such as silver are used as active ingre-
dients diffusing out from the material, the silver ions will be 
detoxified by serum used in cell experiments. If comparisons 
are to be made with bacterial effect, serum at the same concen-
tration as used in the cell experiments should be added in the 
bacterial experiments.[120]
5. Microbiological Testing In Vitro and In Vivo
Contrary to biocompatibility testing (ISO 10993) no formal reg-
ulations exist for the assessment of devices with regard to infec-
tion risk. Thus, there is no formal guidance for medical device 
industries how to evaluate their products with regard to antimi-
crobial properties. Still several testing and validation methods 
of antimicrobial designs exist, some of them are standard-
ized and others are dedicated tests.[121] However, there are no 
standard tests available for testing the antimicrobial efficacy of 
urinary catheters.
For in vitro microbiological testing, several parameters 
should be considered that all might significantly affect the 
obtained data. These include parameters of the experimental 
setup such as medium conditions, choice of microorganism 
(species and strain), inoculum size, and flow conditions. Ide-
ally, experiments should be designed so that they can predict 
the outcome of in vivo tests, in order to reduce the number of 
in vivo experiments. A range of in vitro methods can be used to 
evaluate the efficacy of different types of antifouling or antibac-
terial surfaces (Figure 6). It is important that samples are steri-
lized and kept sterile until microbial exposure, and care needs 
to be taken to avoid contamination during microbial testing. 
As the variability may be high, sufficient numbers of replicates 
(both repeats of experiment and with different microbial inoc-
ulum/cultures) should be performed, in general at least three 
biological replicates should be tested. Negative controls, posi-
tive controls, standard (benchmark) materials, and untreated 
material controls should ideally all be included in every experi-
ment to enable quality control and to allow for better compari-
sons between studies.
5.1. Medium Conditions
Medium conditions should mimic the conditions found in the 
host. For the evaluation of (coatings/materials for) ureteral 
stents, intraluminal surfaces of urinary catheters, or parts 
of devices in the bladder, (artificial) urine should be used as 
incubation medium. When testing extraluminal surfaces of 
(materials for) urinary catheters the authors suggest the cul-
ture medium should be supplemented with small amounts 
of serum, from which various proteins may adsorb onto the 
material surface[122] as an approximation of the extraluminal 
fluid. Not much is known about the constituents of the extra-
luminal fluid but in addition to expressed proteins from 
urothelial cells, it is likely that small damages in the urethral 
lining as a result of catheter passage will lead to low concen-
trations of serum proteins.[123] Serum is chosen, in this appli-
cation, over blood plasma since many of the model organisms 
for UTI are Gram-negatives and their adhesion has been 
reported to decrease after blood plasma pretreatment but not 
after whole blood treatment.[81] Human urine is a fluid with 
a variable pH in the range of 4.5–8.0, it has both intra- and 
interpersonal variable compositions.[124,151] It is hypertonic 
and despite having antimicrobial properties[125] is able to sup-
port bacterial growth up to 108 CFU mL−1.[126] To overcome 
urine variability, studies on uropathogens could be performed 
in large batches of pooled human urine[127] or in artificial 
urine.[125] However, when using pooled urine samples it is 
very difficult to obtain a normalized fluid composition over 
time (between batches) due to the intrinsic high variability. 
For this reason, it may be better to use an artificial urine that 
resembles the composition and physical properties of human 
urine as closely as possible, as outlined and reviewed in the 
literature.[49,125,126,128] For testing of materials aimed for long-
term use in the urinary tract with the pathogen P. mirabilis, 
an alkaline version of the artificial urine can be chosen to 
accurately mimic the conditions for formation of crystalline 
biofilm also during short experimental time spans. For experi-
ments designed to run for long time intervals, these urease-
positive bacteria will by themselves induce this alkalinization, 
as was described for cultivation of P. mirabilis and P. aerugi-
nosa in artificial urine.[126]
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5.2. Microorganisms and Microbial Challenge Dose
The microorganisms used should be representative to a clin-
ical situation, in order to have predictive value. Furthermore, 
the microbial profile for infections of short-term urinary 
devices differs from that of long-term devices. For short-term 
catheterization, S. epidermidis, E. coli, and E. faecalis have been 
described as the most common pathogens[18] while in long-
term catheterization P. aeruginosa, P. mirabilis, Providencia stu-
artii, M. morganii, and K. pneumoniae were most prevalent.[18] 
Although there is no consensus between different studies 
for the topmost prevalent etiological agents of these infec-
tions,[2,129] the most common bacteria isolated were E. coli 
followed by Enterococcus species, which also dominate in short-
term devices. Furthermore, bacterial strains should be selected 
that are good biofilm producers in the relevant medium, thus 
Macromol. Biosci. 2019, 19, 1800384
Figure 6. Schematic box diagram outlining choices of conditions for testing which need to be decided when designing in vitro microbial testing of 
antimicrobial materials for application in the urinary tract (at the top of the figure), and commonly used evaluation methods after bacterial exposure 
(bottom of the figure). Substance identification/characterization in microscopy can for example relate to the use of fluorescent probes identifying 
specific strains of microorganisms in a sample.
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in artificial urine for testing of materials for the urinary tract. 
In this context, it is important to remember that different 
strains from the same bacterial or fungal species may exhibit 
very different phenotypes significantly influencing their ability 
to form biofilm on surfaces[130,131] and their suitability as model 
organisms for testing of materials surfaces. However, at this 
time, information about identified suitable clinically significant 
model strains for testing antimicrobial materials in the urinary 
tract is lacking in the scientific literature.
In 3–32% of patients with short-term catheters, fungi were 
also detected[11] and the majority of these cases included Can-
dida albicans.[132,133] Surveillance data from U.S. National Noso-
comial Infections Surveillance (NNIS) reported C. albicans to be 
the fourth-most important nosocomial pathogen in UTI.[134] The 
highest risk for Candida infection was found for patients with 
immune suppression and long-term catheterization. Addition-
ally, Candida strains frequently exhibit drug resistance.[133] Both 
monospecies and multispecies biofilms have been reported 
including bacteria and/or fungi, and for long-term devices, mul-
tispecies biofilms are very common[18,135] including pathogens 
promoting device encrustation, as previously described.[136]
Besides choosing microorganism used to test an antimicrobial 
or antifouling surface, an appropriate dose also has to be decided 
in a testing protocol. Bacterial numbers in the urogenital area 
can be very high and bacterial titers of up to 108 CFU mL−1 have 
been described in the bladder.[137] This is an important consid-
eration during materials/device testing as devices may be placed 
into an already infected patient, thereby encountering very high 
microbial densities. Standard testing of microbicidal activity gen-
erally minimally requires evidence of three or even four log units 
reduction of viability or growth in comparison to a control. If 
10 µL of a sample aliquot is plated and one cell counted on this 
plate, it corresponds to 100 CFU mL−1. Thus, in order to accu-
rately assess a log-4 reduction on a culture plate, at least 106 CFU 
mL−1 should be used. If 100 µL sample aliquots are used, at least 
105 CFU mL−1 is needed as starting inoculum. Following this, 
testing of urological devices should be performed using bacte-
rial densities of at least 105 CFU mL−1 and ideally in the range 
of 107–109 CFU mL−1, with the possibility to adjust the densities 
with respect to microorganism tested. For fungi such as C. albi-
cans, a density of 105 CFU mL−1 is suggested following the Euro-
pean Committee on Antibiotic Susceptibility Testing (EUCAST) 
recommendations.[138] For antifouling surfaces, higher microbial 
densities may be used in the tests. Furthermore, suitable controls 
should be included to ensure that sample treatment steps such 
as sonication do not affect the viability of microorganisms.[139]
Although separate methods are seldom applied for testing effi-
cacy of extraluminal sides of urological devices of the lower uri-
nary tract, lower doses could be required here. The reason is that 
bacterial concentrations found on the epithelial linings facing 
the extraluminal surface of the devices are presumably much 
lower than in the bladder. Moreover, catheter contamination by 
bacteria in this scenario is due to bacterial transmission between 
surfaces making close contact, rather than via mass transport 
from a liquid volume. Thus, relatively low bacterial concentra-
tions are here suggested in order to avoid that potentially ade-
quate preventive designs fail in the evaluation process. For this 
limited case, 103–104 CFU cm−2 may be used thereby mimicking 
an assumed lower number of pathogens on the urethral surface 
exposed to the extraluminal surface of the catheter, bearing in 
mind that this set-up may not allow a 3–4 log reduction to be 
proven. Since methods used in these cases are typical systems 
with a high area to volume ratio, such as in the JIS Z2801 test 
(see also Section 5.3.1), challenge numbers of bacteria may be 
defined per area as these values can be more relevant than bac-
terial concentrations per volume.[7] However, these extraluminal 
tests may not provide a microbial challenge suitable for intralu-
minal parts of a catheter or devices in the ureter or bladder.
5.2.1. Multispecies Interactions
Interactions occurring between bacteria of different species are 
important to consider when designing CAUTI model test systems. 
As stated above, biofilms on urinary devices are often composed 
of multispecies consortia, especially in long-term catheters.[140] 
Experimental data show that interspecies interactions in bio-
films bring out synergistic effects, also described as community 
intrinsic properties, which are traits expressed only in the pres-
ence of other species. Obviously, these characteristics cannot be 
studied in monocultures.[141] With relevance to UTIs, multispecies 
biofilms have been reported to be more virulent and have higher 
tolerance to antimicrobial agents, than would have been expected 
from assessment of monospecies biofilms studied individually.[142] 
Importantly, some uropathogen species are only able to colonize 
the catheter surface in the presence of others species.[143] In line 
with this, it was recently suggested that interspecies interactions 
between multidrug-resistant organisms should be considered 
when treating CAUTI by antibiotic therapy, as applications of anti-
biotics would select for specific resistant organisms that would 
then positively select for other multidrug-resistant organisms 
through complex network interactions.[144] Interactions resulting 
in enhanced virulence and antibiotic tolerance are not restricted 
to the bacterial kingdom; examples of bacteria–fungi interac-
tions have also been described, mainly focusing on the interac-
tions between S. aureus and C. albicans, where extended S. aureus 
invasion has been reported due to bacterial association to fungal 
hyphae.[145] Therefore, we recommend that these interactions are 
also considered in microbiological assessments of materials and 
antimicrobials. This should be at a later stage, after monoculture 
assessment, and may include testing of defined multispecies com-
binations (representing a CAUTI community). Only by stepwise 
enhancement of complexity, we will enable truly relevant evalua-
tion of catheters and ureteral stents capable of preventing coloni-
zation by relevant microbial communities causing infection.
5.3. Clinical Flow Conditions
Antimicrobial coating designs are usually developed to prevent 
device-associated UTI[79,146] and, in order to do so, all routes 
of infection should be considered and preferably blocked[17] 
including those that may occur on replacement devices in 
previously infected patients. In previously non-colonized 
patients receiving a catheter, the main route along the extralu-
minal side of a urinary catheter, is established under predom-
inantly stationary conditions in a situation with relatively 
low liquid volume. However, in patients where a colonized 
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catheter is replaced, the main route of infection may differ 
depending on where the microorganisms are residing in 
the urinary tract of the colonized patient. Intraluminal col-
onization can be established in very different conditions of 
flow and these depend on the way the catheter is operated. 
Indwelling urinary catheters can be directly connected to a 
drainage bag (free-flow) or they can be fitted with a valve at 
the end of the tube to allow, for instance, voiding into a toilet. 
There are several medical conditions (e.g., people with severe 
cognitive impairment or high pressure chronic retention, 
ureteric reflux or obstructive renal impairment/failure) where 
the use of a catheter valve is not recommended.[147] However, 
it has been shown that using a catheter valve is beneficial to 
decrease the risk of infection,[147] reduce catheter blocking[148] 
and is a more cost-effective solution[147] increasing patient 
comfort.[149] Additionally, it has been shown that using a free-
flow drainage bag for 6 months can lead to bladder shrinkage 
and compromised function[150] whereas the use of a valve 
enables the operation in conditions that mimic the normal 
bladder function[147] maintaining its functionality. Since the 
way the catheter is operated will affect intraluminal flow, with 
reduced flow in free drainage mode or with interrupted and 
varying flow when using a valve, it is difficult to propose a 
standardized condition for in vitro testing. Given the different 
routes of infection and the operation modes of urinary cath-
eters, the evaluation of the efficacy of antimicrobial coatings 
typically requires testing under static and flow conditions.
5.3.1. Static Conditions
In general, standardized microbial testing methods for static 
conditions are more developed than those for flow conditions.[7] 
Among the most applied evaluation methods are “agar zone of 
inhibition” tests, in which antimicrobials released from a func-
tionalized material positioned upside down on an agar plate dif-
fuse into the agar to form a zone of growth inhibition during 
incubation. The diameter of this zone of inhibition indicates 
the amount or efficacy of the released antimicrobial toward the 
applied bacterial or fungal species. Other methods applicable to 
antimicrobial releasing designs are executed in a nutrient sus-
pension. Suspended bacteria exposed to these samples may be 
growth-inhibited or killed in the medium with an efficacy meas-
ured by the numbers of viable bacteria in the suspension or left 
on the sample after incubation. Typical “high area to volume” 
tests apply to situations encountered in the narrow space 
between the catheter and the urethral epithelial layer, which 
create an intimate contact between the microorganisms and the 
sample. Examples of these tests are the standard JIS-Z 2801 and 
“all in one” plating systems (Petrifilm, 3M, St. Paul, MN, USA).[7] 
Since an intimate contact between bacteria and the sample is 
created, these type of tests are also applicable to contact killing 
designs[152] but may be less valuable for repellent systems.
5.3.2. Flow
Under flow conditions, the fluid mechanics of the liquid in con-
tact with, for example, an attaching bacterial cell will affect its 
subsequent adherence, biofilm formation, and biofilm struc-
ture.[153,154] Furthermore, the antimicrobial substrate and its 
interaction with the microbial cell may be highly influenced 
by flow. Contact killing surfaces that are adhesive for micro-
bial cells may be covered in microbial debris and loose (part of 
their) activity,[8,131] and this process may be highly influenced 
by the fluid flow around the surface. Surfaces releasing antimi-
crobial substances exposed to flow may be depleted at shorter 
lengths of time compared to the same set up under static condi-
tions.[155] Therefore, it is important that an experimental set-up 
used to perform assays of biofilm formation is able to mimic 
the flow conditions occurring, for example, in the urinary tract. 
In fact, hydrodynamics determine the rate of transport of cells, 
oxygen, and nutrients to the device surface, as well as the mag-
nitude of the shear forces acting on a developing biofilm.[156] 
Because the flow rate by itself provides little information about 
shear without taking into account the geometry of the applied 
in vitro flow system it is useful to mimic the flow conditions in 
a catheter by using either the wall shear stress or the shear rate 
(See also Box 2).[157,158]
For performing in vitro assays on biofilm formation under 
flow conditions, biofilm reactors are widely used. Although 
standardized methods exist, such as ASTM E2871-13 and 
ASTM 2562-12 for the Center for Disease Control (CDC) biofilm 
reactor, the operation of some of these reactors have specific 
limitations. For example, some of them cannot be used to test 
different materials, some of them have reduced sampling areas 
or, since most biofilm reactors are basically stirred containers, 
the flow pattern changes within the coupon surface and does 
not mimic the plug flow characteristics of a urinary catheter. 
For a more detailed discussion on these platforms, the reader is 
referred to comprehensive reviews on this matter.[157,159] Unfor-
tunately, there are no standardized methods for specifically 
testing materials for the urinary tract. Platforms often used to 
perform in vitro assays for the urinary tract are flow systems 
that mimic flow conditions as well as transport of nutrients and 
bacteria in a device such as a urinary catheter or ureteral stent. 
These can be generally divided into two broad categories: those 
that are designated as bioreactors such as the Robbins device, 
used to study the efficacy of sample surface functionalization 
on biofilm formation and those that are essentially built for 
microscopic observation of individually adhering bacteria, des-
ignated as flow chambers or flow cells.[160] Additional methods 
exist that study larger sections of devices under flow exempli-
fied by Fisher et al.,[161] who designed an in vitro catheter chal-
lenge model by placing a section of a urinary catheter in a 
liquid and exposing the intraluminal side with pulses of bacte-
rial suspensions under flow. Methods utilizing intact catheters 
have been described by Chua et al.[162] and Stickler et al.,[49,163] 
allowing for flow and bacterial exposure of the intraluminal 
side of urinary catheters, as well as the formation of a stagnant 
urine pool around the inflated balloon.
Robbins Device and Modifications: The Robbins device is 
mainly operated as a biofilm reactor allowing a continuous flow 
of fresh growth medium and is based on the designs of Jim 
Robbins and Bill McCoy that were later patented by the Shell 
Oil Company.[164] They are essentially pipes containing holes 
in which screws are fixed. These screws, which are aligned 
parallel to the fluid flow direction, contain coupons that can 
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be independently removed.[165] The modified Robbins device 
(MRD) is basically a square-channel pipe with coupons fixed to 
sampling plugs that can be unscrewed from the walls.[164] These 
plugs are flush (even) with the inner surface and therefore the 
coupon surfaces do not disturb the flow characteristics.[164] 
Other designs include a half-pipe geometry that more closely 
resembles the circular section of a tube.[154] It has been shown 
that the shear stress field is approximately the same in the 
curved and flat walls of these devices[166] so that coupons can 
be placed on the flat wall for convenience and still be subjected 
to the same shear forces acting on the curved wall. The MRD 
can be operated either in laminar or turbulent regime[166–168] 
but it is important to make sure that, particularly in turbulent 
operation, the MRD has an entry section long enough to allow 
complete flow development before the area where the coupons 
are located. This is an important aspect as, otherwise, the shear 
stress field is not constant, and therefore large coupon-to-
coupon variation will arise, or even large variations on a single 
coupon surface. Validation of these flow cells for a predeter-
mined flow rate can be done using particle image velocity (PIV) 
techniques[169] and simulation of the flow by computational 
fluid dynamics.[166,168] MRDs contain a relatively high number 
of coupons (usually between 8 and 20) that enable destructive 
analysis of the biofilm in a long time-course assay[170] or the 
simultaneous testing of different surfaces. However, they are 
not designed to allow direct observation of the biofilm develop-
ment and therefore coupons must be removed for examination, 
which can introduce artefacts due to sample handling.[171]
Flow Cells: There are several commercially available models 
of flow cells that can be mounted on a microscope stage and 
used with video capture systems enabling real-time observation 
of microbial adhesion and biofilm formation.[164] Some models 
are autoclavable, reusable, and compatible with confocal and 
epifluorescence microscopes[172] and the most common geom-
etries are the flat plate and capillary flow cells.
Flat plate flow cells can contain one or two glass viewing ports 
(Figure 7). Models with two channels enable direct comparison 
of biofilms formed under two different conditions (a control and 
a specific treatment) in parallel. Some of the flat plate models 
include recesses to fit coupons that can be constructed from dif-
ferent materials to simulate cell adhesion to different surfaces 
although the low amount of biofilm that is produced may pre-
clude further chemical/biochemical analysis. Flat plate flow 
cells are usually restricted to lower flow rates and to laminar 
flow applications, whereas capillary flow cells can be used at 
Macromol. Biosci. 2019, 19, 1800384
Figure 7. Drawings of flat plate flow cells designed to enable in situ 
microscopic analysis of biofilm formation onto sample coupons (top 
image) or (coated) glass slides (bottom image) that can be used with 
transmission, fluorescence, or confocal microscopy.
Box 2 Equations useful for mimicking flow conditions of 
catheters in parallel plate flow cells.
The main characteristics of flow in a tube are the wall 
shear rate and shear stress. The wall shear rate σ (with 
unit s−1) is a measure of change of the fluid velocity near 
the wall of the tube in the radial direction toward the 
center of the tube. The shear rate is related to the force 
which the fluid flow exerts on the wall, expressed as 
the shear stress τ (N m−2), according to τ = µ ×  σ with 
µ the dynamic viscosity of the fluid (for water around 
10−3 Ns m−2).
The wall shear rate (σ) for a cylindrical geometry, 
assuming that the fluid velocity is zero at the surface and 
flow is laminar in the bulk, is given by:
4
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With Q the flow rate (m3 s−1) and r the radius of the 
catheter (m).
The wall shear rate (σ) for a rectangular channel geom-
etry of a parallel plate flow cell is:
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With h0 the height of the channel (m) and w0 the width 
of the channel (m).
In order to mimic the flow conditions of a urinary cath-
eter in a parallel plate flow cell, the dimensions of the flow 
cell and volume flow should relate to the ones in the cath-
eter according to
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Assuming that the flow rate in the parallel plate flow 
chamber is taken equal to the one in the catheter, a flow 
chamber with a channel height 0.5 mm and channel width 
of 20 mm would mimic the flow characteristics of a cath-
eter with an inner diameter of 2 mm.
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higher flow rates but they are not very convenient for surface 
testing. For turbulent flow regimes, one must make sure that 
the flow cell is long enough to allow for full development of the 
flow in the viewing region (Figure 8).[173] Also sudden expan-
sions or contractions between the connective tubing and the 
flow cell should be avoided to minimize entry effects.[169,174]
Operating Conditions: Flow cells and MRDs have been used 
to study bacterial cell adhesion and biofilm formation under 
hydrodynamic conditions that mimic the urinary tract.[158,170,173] 
In both types of systems, the flow rate should be adjusted to 
an average shear rate of around 15 s−1 as an estimate of the 
intraluminal urine flow, considering a daily production of urine 
around 1.4 L,[151] an inner catheter diameter of 2 mm, and 
assuming operation in free drainage mode (see Section 5.3 and 
Box 2).[175] In general, in order to mimic the shear conditions of 
a urinary catheter in a parallel plate flow cell, the dimensions 
of the flow cell or the flow rate should be adjusted[166,173,176] to 
approach the required shear rate (Box 2).
5.4. Evaluation
Independent of the microbial test selected, the last step is 
always the evaluation after bacterial/fungal exposure. Since 
several reviews on this topic have been published,[7,177] we 
here only include a brief overview (Figure 6). Culture methods 
on agar-plates are the classic, gold standard microbiological 
approach resulting in enumeration of viable bacteria, quanti-
fied by counting CFUs in a defined volume or area. However, 
the disadvantages are that this is time consuming and only 
suitable for culturable microorganisms.[7,164] Methods that 
that do not require cultivation are based on the evaluation of 
metabolic activity of microorganisms using assays such as 
the neutral red uptake, MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide) or XTT (2,3-bis-(2-methoxy-
4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide) assays. 
However, these methods do not show whether the microorgan-
isms are dead or only growth-inhibited, and they are not consid-
ered as validated and standardized as CFU counts are. Another 
possibility is the use of microscopy techniques allowing for the 
in situ analysis of organism morphology, bacterial activity,[178] 
as well as identification of microorganisms, for instance with 
fluorescence in situ hybridization (FISH, Figure 2).[179] Biofilms 
can also be visualized by staining of the biofilm extracellular 
matrix using specific probes[180] or using electron microscopy. 
However, these approaches generally do not provide informa-
tion about numbers of viable bacteria.
A recent review of standardized testing methods has identi-
fied a shortage of suitable standard methods for testing anti-
microbial materials or systems, especially methods allowing 
for testing under flow conditions.[7] In the absence of standard-
ized methods, a multitude of experimental methods have been 
used around the world with the unfortunate consequence that 
studies of antimicrobial coatings or materials in the scientific 
literature are more or less impossible to compare. For example, 
large variability will often be obtained through the choice of 
test organism, medium composition, and flow conditions. Rec-
ommendations on tests to be used may best be derived from 
patient scenarios and the type of devices used. Table 2 summa-
rizes the extremes expected during conditions encountered for 
catheters and ureteral stents. Extraluminally, flow as well as the 
bacterial numbers challenging the catheter surface will always 
be low. Intraluminally, flow will be low in case of free-flow cath-
eters, but high during voiding in case of valve-controlled cathe-
ters. The “challenge dose” of bacteria will particularly depend on 
the colonization status of the bladder. In case of advanced stage 
UTI, the numbers of bacteria in the urine from the bladder will 
be (very) high. Therefore, the worst-case scenario for challenge 
of the catheter would be the situation of a patient with advanced 
stage UTI bladder colonization in combination with a free-flow 
catheter. In this case, the intraluminal surface of the catheter is 
likely to be at the highest risk for colonization and biofilm for-
mation. The most robust testing of antimicrobial activity there-
fore should be performed with high inoculum under low or no 
flow. The test to assess the numbers of adherent bacteria can be 
any test validated with the gold standard of CFU assessment for 
bacteria in case of culturable bacteria. In case numbers of non-
culturable bacterial species need to be assessed, this can most 
robustly be performed quantitatively by qPCR. For the analysis 
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Figure 8. Shear stress at the bottom wall of a parallel plate flow cell, 
illustrating the turbulence and altered flow conditions that may occur, 
for example, at the inlet of the flow cell. Reproduced with permission.[173] 
Copyright 2014, Elsevier.
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of spatial arrangement of different bacterial species within mul-
tispecies biofilms, FISH would be recommended.
5.5. In Vivo Urinary Tract Infection Models
The translation of novel antimicrobial material and device 
technologies for the urinary tract to the clinic has proven to be 
challenging. Preclinical in vivo testing is an important phase 
to design, produce, and reliably test the efficacy of any new 
antimicrobial-functionalized device. Preclinical in vivo studies 
mimic the pathogenesis of UTI in much greater complexity 
than is possible in vitro. Next to the valuable scientific insights 
such studies provide, they are often required by regulatory 
bodies for safety and efficacy evaluation of devices prior to their 
clinical testing and use in patients.[181] A wide range of pre-
clinical in vivo UTI models are available with different levels of 
complexity, ranging from small rodent models to larger animal 
models. Thus, models are available for initial testing/screening 
of novel material and/or antimicrobial strategies in vivo. This 
includes subcutaneous mouse models,[30,182] non-functional 
implant models, such as murine[183] or rat UTI[184] models, to 
fully functional device models, like the rabbit ureteral stent[52] 
and female pig catheter models.[185] Two comprehensive reviews 
on in vitro and in vivo model systems to study biofilm forma-
tion include a detailed overview of the UTI animal models 
currently available.[186,187] However, most emphasis in these 
models is on testing monospecies bacterial infections. There 
have been only a limited number of in vivo studies reported 
on fungal[188,189] and multispecies experimental UTI.[190] This 
reflects the relatively low level of interest in fungal and multi-
species testing in vivo despite indications of synergies such as 
those previously described.[190]
The majority of in vivo models for device-related infection 
in the urinary tract are performed using clinical microbial iso-
lates from hospitalized patients. This is clearly illustrated by the 
review by Lebeaux et al. in 2013 in which all models were using 
clinical isolates or pathogens that had been shown to cause 
UTI in the respective animals.[187] Their review lists two mouse 
models, three rat models, and two rabbit models (Table 3) 
that were using one or several strains of E. coli, P. aeruginosa, 
P. mirabilis and E. faecalis to study device-associated UTI. The 
presence of a device was mimicked by pieces of catheter or 
stent in the bladder, glass beads in the bladder, or in one of 
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Table 2. Combinations of flow conditions and bacterial challenge in different patient scenarios.
Patient condition Catheter free-flow or with valve Bacteria intra/extraluminally Bacterial challenge concentration Flow low/high
Non-colonized patient Either Extraluminally Low Low
Patient with bladder colonization/UTI Free-flow Extraluminally Low Low
Intraluminally High Low
Patient with bladder colonization/UTI Valve Extraluminally Low Low
Intraluminally High High
Stent Bacteria intra/extraluminally Bacterial challenge concentration Flow low/high
Non-colonized patient Extraluminally Low Low
Intraluminally Low Low
Patient with bladder colonization/UTI Extraluminally High Low
Intraluminally High Low
Table 3. Diversity of strains used for in vivo models of device-associated UTI.
Model Model type Species Strains Reference
Mouse Precolonized catheter segment (surgical) in bladder E. coli Uropathogenic K12 EMG2 [191]
Mouse Catheter segment in bladder (both precolonized and with 
inoculation inside bladder)
E. coli
P. aeruginosa
P. mirabilis
E. faecalis
Cystitis isolate of UTI89
ATCC 19660
ATCC 51286
OG1RF wild type and mutant strains
[192]
Rat Precolonized glass beads in bladder E. coli UTI isolate HM32 strain [193]
Rat Ureteral stent segment (surgical) in bladder, inoculated 
inside the bladder
P. aeruginosa clinical isolate AN207, a slime producer [194]
Rat Tube segment in bladder, inoculated in the bladder P. aeruginosa UTI isolate 910735 [195]
Rabbit Ureteral stent/catheter in bladder (both precolonized and 
inoculated in the bladder)
P. aeruginosa
P. mirabilis
Not specified
296 (clinical isolate)
[52,196]
Rabbit Urethral catheter, inoculated after catheterization E. coli WE 6933, causing UTI [197]
Mouse Catheter segment (surgical), inoculated after catheterization C. albicans ATCC SC5314 [189]
Rat Catheter segment, inoculated after catheterization C. albicans K1, DAY185 [188]
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the rabbit models through placement of a urethral catheter. In 
some cases, the materials had a bacterial biofilm pregrown on 
their surface before placement into the bladder of the animals.
It is difficult to base any recommendation of strain selection 
on this literature review. It seems most studies have selected 
their unique strains and no comparisons between how these 
strains colonize or infect the material/device or the surrounding 
tissue are available. For the future, it could be of great value to 
identify a selection of clinical isolates that are well character-
ized, stable, and that could be used for both in vitro and in vivo 
testing of antimicrobial and antifouling materials.
6. Conclusions
The market for clinical care products is conservative, specifi-
cally in case of urinary catheters, which are considered as low-
price products, often as a result of tenders driven to cut medical 
costs. The urinary catheter market is growing globally and will 
reach an annual volume of $2.19 billion by 2022. In contrast to 
the size of the catheter market, national cost estimate from 2015 
suggests that the annual total additional costs associated with 
CAUTI in the United Kingdom is £1–2.5 billion and in United 
states is $36 billion, factors higher than the global total costs 
associated with catheter purchasing. The high risk of infection 
and its associated costs clearly underlines the need to provide 
patients with devices with the lowest possible risk of infection, 
and emphasizes the need for innovative products that reduce 
the incidence rate of device-associated UTI. Although standards 
are available for guiding the development of new devices with 
respect to biocompatibility (ISO 10993) and material charac-
terization (Table 1), no such guidance exists for development 
of antimicrobial devices. Therefore, this review provides rec-
ommendations for design of standard test methods in addition 
to those provided in ISO 10993 for material and device safety. 
The considerations and recommendations presented and sum-
marized in Box 3 cover relevant aspects of antimicrobial mate-
rial testing, including surface characterization, in vitro and in 
vivo tests, strain selection, and hydrodynamic conditions, com-
plying to the complex pathology of device-associated UTI. Such 
standard assays would enable comparisons of results obtained 
in different research labs both in industry and academia, as 
well as provide industry and academia with tools to assess the 
antimicrobial and/or antifouling properties for urinary tract 
devices in a reliable and relevant way.
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Box 3 Recommendations for experimental design of  
in vitro antimicrobial urinary device testing.
• Biological testing should be performed in combination 
with thorough material characterization.
• Protocols should include test medium consisting of 
either large batches of pooled human urine or artifi-
cial urine. This medium is suggested for testing of the 
majority of surfaces of urinary tract devices, with the ex-
ception of extraluminal surfaces in the urethra, where 
addition of small amounts of serum is suggested to 
mimic the extraluminal interface with epithelial cells.
• Preconditioning of materials/devices with culture me-
dium should be investigated using biologically relevant 
fluids above.
• Sterilization procedures for materials and devices 
should be developed and their effects on the materials/
devices investigated.
• The microbial loading should ideally be 107–109 CFU 
mL−1 for bacteria and 105 CFU mL−1 for fungi.
• The type of microorganisms (species and strains)
○ Short-term devices: we suggest performing tests 
with the bacteria E. coli and E. faecalis as well as with 
the fungus C. albicans.
○ Long-term stents and catheters with the complica-
tion of encrustation development: we suggest to in-
clude tests using P. mirabilis and P. aeruginosa. The 
experiments can be shortened by using an artificial 
urine that is already alkaline.
○ Despite clinical biofilms often being composed of 
several species, we suggest using monospecies sys-
tems until stable multispecies consortia have been 
developed and tested in the scientific literature. More 
research is needed trying to understand the ecology 
of multispecies microbial colonization and cohabita-
tion in the urinary tract.
○ The chosen strains should be clinical isolates re-
covered from urinary tract devices, which are good 
biofilm producers under the conditions used during 
testing. Suitable strains should be characterized and 
made available to the scientific community through 
deposition in culture collections.
○ Strains should be chosen that are also suitable for in 
vivo evaluations.
• For testing of extraluminal surfaces in the urethra, static 
conditions or near-static conditions should be used. 
Typical tests which apply in situations encountered in 
the narrow space between the catheter and the urethral 
epithelial layer are the standard JIS-Z 2801 and “all in 
one” plating systems. These surfaces may be challenged 
with lower bacterial inoculum.
• For the intraluminal surfaces in the urethra, blad-
der, or devices in the ureter a setup allowing for flow 
is required to mimic what happens in vivo. Flow cells 
are suggested as experimental setups, since they may be 
easily designed to accurately mimic flow conditions in 
the device.
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which testing of medical devices aimed at preventing infection should be 
performed to follow best practices, as well as to enhance the predictability 
of methods for clinical outcome of a device with respect to infection. 
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